Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patients

BACKGROUND: In January 2014, the European Medicines Agency issued a marketing authorization for dolutegravir (DTG), a second-generation integrase strand transfer inhibitor for HIV treatment. The study aimed at determining the incremental cost-effectiveness ratio (ICER) of the use of DTG+backbone com...

Descripción completa

Detalles Bibliográficos
Autores principales: Restelli, Umberto, Rizzardini, Giuliano, Antinori, Andrea, Lazzarin, Adriano, Bonfanti, Marzia, Bonfanti, Paolo, Croce, Davide
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5499774/
https://www.ncbi.nlm.nih.gov/pubmed/28721059
http://dx.doi.org/10.2147/TCRM.S135972

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5499774/
https://www.ncbi.nlm.nih.gov/pubmed/28721059
http://dx.doi.org/10.2147/TCRM.S135972

Ejemplares similares